# Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

> **NCT02456701** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **BIOLOGICAL:** KTN3379
- **DRUG:** vemurafenib

## Key facts

- **NCT ID:** NCT02456701
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-10-13
- **Final completion:** 2016-10-13
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02456701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02456701, "Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02456701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*